94 related articles for article (PubMed ID: 9853452)
1. Chemoprevention controversies continue.
Lebeau D
Lancet; 1998 Nov; 352(9141):1683. PubMed ID: 9853452
[No Abstract] [Full Text] [Related]
2. [Cyclooxygenase 2 inhibitors and cancer chemoprevention].
Masmoudi A; Le Chevalier T; Sabatier L; Soria JC
Bull Cancer; 2004 May; 91 Spec No():S77-84. PubMed ID: 15239334
[TBL] [Abstract][Full Text] [Related]
3. Herbal medicine, cancer prevention and cyclooxygenase 2 inhibition.
Izzo AA; Capasso F
Trends Pharmacol Sci; 2003 May; 24(5):218-9. PubMed ID: 12767718
[No Abstract] [Full Text] [Related]
4. [Cyclo-oxygenase 2 inhibitors and cancer].
André T; Soria JC
Bull Cancer; 2004 May; 91 Spec No():S59-60. PubMed ID: 15239332
[No Abstract] [Full Text] [Related]
5. Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy.
Onn A; Tseng JE; Herbst RS
Clin Cancer Res; 2001 Nov; 7(11):3311-3. PubMed ID: 11705841
[No Abstract] [Full Text] [Related]
6. Cyclooxygenase-2: a molecular target for chemoprevention of epithelial tumors of skin and colon.
Müller-Decker K; Charyalertsak S; Albert C; Reinerth G; Marks F; Fürstenberger G
Adv Exp Med Biol; 2002; 507():445-8. PubMed ID: 12664624
[No Abstract] [Full Text] [Related]
7. Controversies in COX-2 inhibitor therapy. Introduction.
Abramson SB
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S1-2. PubMed ID: 11695245
[No Abstract] [Full Text] [Related]
8. Chemoprevention of intestinal polyposis by COX-2 inhibition: from mouse to man.
Bresalier RS
Gastroenterology; 2002 Jan; 122(1):234-6. PubMed ID: 11781300
[No Abstract] [Full Text] [Related]
9. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Koga H
Cancer; 2003 Aug; 98(4):661-7. PubMed ID: 12910508
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms underlying chemoprevention of ovarian cancer.
Mills GB
Clin Cancer Res; 2002 Jan; 8(1):7-10. PubMed ID: 11801533
[No Abstract] [Full Text] [Related]
11. Sizing up the new arthritis drugs.
Johns Hopkins Med Lett Health After 50; 1999 Aug; 11(6):1-2. PubMed ID: 10453710
[No Abstract] [Full Text] [Related]
12. Cutting-edge pharmacotherapeutics.
Mege J
Pa Med; 1998 Dec; 101(12):17, 22. PubMed ID: 9883028
[No Abstract] [Full Text] [Related]
13. Current application of selective COX-2 inhibitors in cancer prevention and treatment.
Stratton MS; Alberts DS
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):37-51. PubMed ID: 12102579
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase 2 inhibitors.
Kelley KW; Ramsey LA
Adv Nurse Pract; 2003 Mar; 11(3):22-4. PubMed ID: 12683165
[No Abstract] [Full Text] [Related]
15. Controversies in COX-2 inhibitor therapy: closing remarks.
Abramson SB; Furst DE; Hochberg MC; Patrono C
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S77-80. PubMed ID: 11695257
[No Abstract] [Full Text] [Related]
16. Cyclooxygenase-2 inhibitors: will they help us prevent diabetic nephropathy?
Zatz R; Fujihara CK
Kidney Int; 2002 Sep; 62(3):1091-2. PubMed ID: 12164896
[No Abstract] [Full Text] [Related]
17. Characteristics of COX2 inhibitors questioned.
Petit-Zeman S
Nat Rev Drug Discov; 2004 Sep; 3(9):726-7. PubMed ID: 15368654
[No Abstract] [Full Text] [Related]
18. [Selective inhibitors of cyclooxygenase-2: new perspectives of human diseases management].
Nasonov EL; Tsvetkova ES; Tov NL
Ter Arkh; 1998; 70(5):8-14. PubMed ID: 9644734
[No Abstract] [Full Text] [Related]
19. [Thinking about the specific cyclooxygenase-2 inhibitors since its recommendation].
Shi G
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):579-80. PubMed ID: 11758234
[No Abstract] [Full Text] [Related]
20. [COX-2 inhibitors: current status and outlook].
Dannhardt G; Hahn L
Pharm Unserer Zeit; 2000 Mar; 29(2):100-6. PubMed ID: 10763335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
